Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell membrane-specific peptide receptors, such as somatostatin receptors (SSTRs), and of which gastroenteropancreatic (GEP), carcinoid and pancreatic islet cell tumours exhibit the highest expression of...
| Autors principals: | , , , |
|---|---|
| Format: | Journal article |
| Idioma: | English |
| Publicat: |
2005
|